Skip to main content
Evidence Snapshot

Ribosomal protein S6 kinase alpha-3

CHEMBL2345 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2345
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosomal protein S6 kinase alpha-3 as ChEMBL target CHEMBL2345, mapped to UniProt P51812. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosomal protein S6 kinase alpha-3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2345
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P51812
Ribosomal protein S6 kinase alpha-3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Ribosomal protein S6 kinase alpha-3 matters

As of 2026-09-14

Ribosomal protein S6 kinase alpha-3 is reviewed as Ribosomal protein S6 kinase alpha-3 (UniProt P51812); the current evidence base includes 12 approved drugs, 2937 compounds, and 707 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 2937 compounds, and 707 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Ribosomal protein S6 kinase alpha-3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P51812, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2937
Total Compounds
707
Total Assays
12
Approved Drugs
IC50: 624.0, KI: 1034.0, EC50: 9.0, KD: 391.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 10.1 IC50 —
No preferred name
CHEMBL3673622
 9.7 IC50 —
No preferred name
CHEMBL3673631
 9.6 IC50 —
No preferred name
CHEMBL4292020
 9.5 IC50 —
No preferred name
CHEMBL3673624
 9.5 IC50 —

Approved Drugs

Structure Compound First Approval
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
PALBOCICLIB
CHEMBL189963
 2015
NINTEDANIB
CHEMBL502835
 2014
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2345